NCT06918587View on ClinicalTrials.gov

Open Label Randomized Comparative Crossover Pharmacokinetic and Immunogenicity Study

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

September 5, 2024

Primary Completion Date

February 2, 2025

Study Completion Date

April 30, 2025

Conditions
Febrile Neutropenia
Interventions
DEVICE

TPI-120 with On body injector

6mg Subcutaneous injection

DRUG

Fylntera

6mg subcutaneous

Trial Locations (1)

Unknown

Not Disclosed, Jordan

Sponsors
All Listed Sponsors
lead

Kashiv BioSciences, LLC

INDUSTRY